Alliance with DFCI for Anti-Infective Research
AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its AbD Serotec unit entered a research and supply agreement with the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (DFCI) in Boston. Dana-Farber is engaged in research activities within a project funded by the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense, to develop transient immunity against life-threatening viral infections. AbD Serotec will provide the laboratory of Wayne Marasco, MD, PhD with research tools using its proprietary Slonomics technology platform. AbD Serotec will receive financial compensation and has preferred access to commercialization rights for products generated during the collaboration.
“We are delighted to provide a world-class research organization with innovative research tools. This alliance can lead to both short- and long-term value for AbD Serotec and the entire MorphoSys group in the infectious disease area,” commented Dieter Feger, Senior Vice President and Head of AbD Serotec.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company’s HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world’s leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a firstin-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol “MOR”. For further information, visit www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and Slonomics® are registered trademarks of MorphoSys; arYlaTM is a trademark of MorphoSys.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors@morphosys.com